|
000
| 01735cas 2200337zi 4500 |
|---|
| 001 | 9.507462 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107133801 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150406d20072015oncar p o f0 a0eng|d |
|---|
| 022 | |a2292-3136 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH79-5E-PDF|zH79-5/2015E-PDF |
|---|
| 245 | 00|aNew drug pipeline monitor. |
|---|
| 264 | 1|aOttawa, ON : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c2007-2015. |
|---|
| 310 | |aAnnual (Irregular) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline ressource|bcr|2rdacarrier |
|---|
| 362 | 1 |aBegan with 2007; ceased with 2015. |
|---|
| 500 | |a"National Prescription Drug Utilization Information System (NPDUIS)." |
|---|
| 500 | |aIssued also in French under title: L'observateur des médicaments émergents. |
|---|
| 520 | |a"The New Drug Pipeline Monitor (NDPM) provides information on drugs currently under development that may have an impact on future drug plan expenditures in Canada. This publication contains a select list of pipeline drugs that are in Phase III clinical trials or under review by the US Food and Drug Administration (FDA) and that demonstrate the potential to have a significant clinical impact. The BioPharm Insight database is the main data source for this drug selection"--Executive summary, 2014. |
|---|
| 692 | 07|2gccst|aDrugs |
|---|
| 692 | 07|2gccst|aResearch and development |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board. |
|---|
| 775 | 08|tL'observateur des médicaments émergents.|w(CaOODSP)9.503855 |
|---|
| 785 | 00|tMeds pipeline monitor ...|w(CaOODSP)9.868374 |
|---|